Long-Lasting Remission of Pulmonary Metastases of Renal Cell Cancer under IFN-b Therapy in a Patient with Multiple Sclerosis

Anne Flörcken(Humboldt-Universität zu Berlin), Jörg Westermann(Palmetto Hematology Oncology), Hella Gollasch(Helios Hospital Berlin-Buch), Timm Denecke(Leipzig University), Gernot Reich(Palmetto Hematology Oncology), Albrecht Kretzschmar(Roche (Switzerland))

Oncology Research and Treatment

January 1, 2006

10.1159/000094540

Cited by 2

Related Papers

Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

|European Journal of Cancer|2011|615

Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study

|Annals of Oncology|2009|534

Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Leucovorin Plus Oxaliplatin in Metastatic Colorectal Cancer: A Final Report of the AIO Colorectal Study Group

|Journal of Clinical Oncology|2007|281

Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial

|Annals of Oncology|2005|223

Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial

|Journal of Clinical Oncology|2023|212